B of A Securities Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $149

B of A Securities analyst Tazeen Ahmad has maintained a 'Buy' rating on Rhythm Pharmaceuticals (NASDAQ: RYTM) and raised the price target from $139 to $149. This adjustment reflects a positive outlook for the company's stock performance.